PT  - JOURNAL ARTICLE
AU  - Ital Nemet
AU  - Limor Kliker
AU  - Yaniv Lustig
AU  - Neta S. Zuckerman
AU  - Oran Erster
AU  - Carmit Cohen
AU  - Yitshak Kreiss
AU  - Sharon Alroy-Preis
AU  - Gili Regev-Yochay
AU  - Ella Mendelson
AU  - Michal Mandelboim
TI  - Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
AID  - 10.1101/2021.12.13.21267670
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.13.21267670
4099  - http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267670.short
4100  - http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267670.full
AB  - Using isolates of SARS-CoV-2 WT, Beta, Delta and most importantly Omicron we studied the capability of the BNT162b2 vaccine given in two or three doses to neutralize major SARS-CoV-2 variants of concern (VOC).We demonstrate low neutralization efficiency against delta and wild-type for vaccines with more than 5 months following the second BNT162b2 dose, with no neutralization efficiency against Omicron. We demonstrate the importance of a third dose, by showing a 100-fold increase in neutralization efficiency of Omicron following a third dose, with a 4-fold reduced neutralization compared to that against the Delta VOC. The durability of the effect of the third dose is yet to be determined.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the Sheba Medical Center institutional review board (7045-20-SMC). Patient consent was waived because the study used remains of clinical samples and the analysis used anonymous clinical data. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors